SFB 1181: Checkpoints for Resolution of Inflammation

SFB 1181：炎症消退的检查点

• 批准号: 261193037
• 金额: --
• 依托单位: Friedrich-Alexander-Universität Erlangen-Nürnberg
• 依托单位国家: 德国
• 项目类别: Collaborative Research Centres
• 财政年份: 2015
• 资助国家: 德国
• 起止时间: 2014-12-31 至 2023-12-31
• 项目状态: 已结题
• 来源: https://gepris.dfg.de/gepris/projekt/261193037?language=en
• 关键词: SFB; 1181; Checkpoints; Resolution; Inflammation

Inflammation is the most important defense strategy of the body. Inflammation needs to be resolved, when no longer needed. Impaired resolution of inflammation leads to chronic diseases like arthritis, colitis and asthma. CRC1181 aims to define the mechanism of resolution of inflammation and to identify pathways that support the resolution process as well as those that overcome resolution and lead to chronicity of inflammation. In the last two funding periods we have defined critical nodes that control tissue specific resolution of inflammation. Furthermore, new methods have been developed that allow to study the dynamics of inflammation in vivo. In addition, therapeutic approaches have been discovered that foster resolution of immune-mediated inflammatory diseases. In the third funding period, we will leverage on (i) new insights in the immune metabolism during resolution of inflammation, (ii) therapeutic approaches to allow reset of inflammation and (iii) technologies that provide an unprecedented view in tissue changes during inflammation. To accomplish these goals CRC1181 has substantially restructured its team of scientists and has integrated new technologies. This strategy will push innovation and create new insights in the mechanisms and therapeutic approaches to stop inflammation in human disease during the third funding period.

炎症是身体最重要的防御策略。当不再需要时，需要解决炎症。炎症消退受损会导致慢性疾病，如关节炎、结肠炎和哮喘。CRC1181旨在定义炎症消退的机制，并确定支持消退过程的途径以及克服消退并导致炎症慢性化的途径。在过去的两个资助期间，我们已经定义了控制炎症组织特异性解决的关键节点。此外，已经开发了允许研究体内炎症动力学的新方法。此外，已经发现了促进免疫介导的炎性疾病消退的治疗方法。在第三个资助期，我们将利用（i）炎症消退期间免疫代谢的新见解，（ii）允许炎症重置的治疗方法和（iii）提供炎症期间组织变化的前所未有的视图的技术。为了实现这些目标，CRC1181大幅重组了其科学家团队，并整合了新技术。这一战略将推动创新，并在第三个资助期内对机制和治疗方法产生新的见解，以阻止人类疾病中的炎症。